It may be time to start applying the brakes to oncology drug development.
Perhaps surprisingly, that’s the opinion of the US Food and Drug Administration’s Oncology Center of Excellence director Richard Pazdur. The breakthrough era of targeted oncology drugs has resulted in an...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?